U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H26NO2.Na
Molecular Weight 359.4371
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINEPTINE SODIUM

SMILES

[Na+].[O-]C(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3

InChI

InChIKey=RXWWSYJKVIBAAU-UHFFFAOYSA-M
InChI=1S/C22H27NO2.Na/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22;/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C22H26NO2
Molecular Weight 336.4473
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Survector

Approved Use

Survector 100mg tablet is used in the treatment of depression.

Launch Date

2.52460794E11
PubMed

PubMed

TitleDatePubMed
[Amineptine-induced cholestatic hepatitis. 5 cases (author's transl)].
1980 Dec 20
[The problem of side-effects: cardiotoxicity (author's transl)].
1981
[Hepatitis caused by amineptine : a case with reintroduction of the drug].
1981 Nov
[Effects of thymo-analeptics and acceptability of amineptin compared to those of imipramine].
1982
[A study of three potential antidepressants (amineptin, mianserin and nomifensin) on the cardiovascular system and isolated intestine (author's transl)].
1982 Jun 10
[Value of amineptin in the treatment of different depressive states. Apropos of 112 cases treated as part of a national multi-centric study].
1985 Jul-Aug
[Rosaceous drug eruption caused by amineptin (Survector)].
1988
[Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases].
1988
[Acneiform eruption induced by amineptin (Survector)].
1989
Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant.
1989 Aug
[Amineptin dependence. Detection of patients at risk. Report of 8 cases].
1990 Sep-Oct
[Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance].
1990 Sep-Oct
[Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case].
1991 Dec
[Immediate acute hepatic cytolysis after the administration of a single amineptin tablet].
1992
[Acne induced by amineptin: adnexal toxiderma].
1996
Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study.
1997 Sep
[A case of Parkinson syndrome secondary to combined amineptine and bromazepam abuse].
1998 Sep-Oct
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Social stress in anorexia nervosa: a review of immuno-endocrine relationships.
2001 Jun
Dopaminergic augmentation of sleep deprivation effects in bipolar depression.
2001 Nov 30
Methylphenidate in stimulants abuse: three case reports.
2001 Spring
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
2002 Dec
Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.
2003
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies.
2004 Aug
Discriminating different classes of toxicants by transcript profiling.
2004 Aug
Fluoxetine dependence in a former amineptine abuser.
2004 Oct-Dec
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation with molybdenum and thiocyanate.
2006 Dec
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation using methyl orange and bromocresol green reagents.
2006 Sep
[A case of tianeptine abuse].
2006 Spring
Is it possible to be dependent to Tianeptine, an antidepressant? A case report.
2007 Apr 13
Utility of 7,7,8,8-tetracyanoquinodimethane charge transfer reagent for the spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides.
2007 Dec 31
Addressing the paradoxes of satisfaction with hospital care.
2008
Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse.
2008 Sep
Improving pain management communication: how patients understand the terms "opioid" and "narcotic".
2008 Sep
Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability.
2009
Treatment for amphetamine withdrawal.
2009 Apr 15
[Acne induced by amineptine].
2009 Jan-Feb
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.
2009 Jun
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Research on antidepressants in India.
2010 Jan
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/21584062
Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.
Route of Administration: Oral
In Vitro Use Guide
Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:40:06 UTC 2023
Edited
by admin
on Thu Jul 06 00:40:06 UTC 2023
Record UNII
6BYR55117P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINEPTINE SODIUM
WHO-DD  
Common Name English
7-((10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO)HEPTANOIC ACID, SODIUM SALT
Common Name English
Amineptine sodium [WHO-DD]
Common Name English
HEPTANOIC ACID, 7-((10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO)-, SODIUM SALT (1:1)
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID70219006
Created by admin on Thu Jul 06 00:40:06 UTC 2023 , Edited by admin on Thu Jul 06 00:40:06 UTC 2023
PRIMARY
SMS_ID
100000085154
Created by admin on Thu Jul 06 00:40:06 UTC 2023 , Edited by admin on Thu Jul 06 00:40:06 UTC 2023
PRIMARY
EVMPD
SUB00448MIG
Created by admin on Thu Jul 06 00:40:06 UTC 2023 , Edited by admin on Thu Jul 06 00:40:06 UTC 2023
PRIMARY
CAS
68946-01-0
Created by admin on Thu Jul 06 00:40:06 UTC 2023 , Edited by admin on Thu Jul 06 00:40:06 UTC 2023
PRIMARY
FDA UNII
6BYR55117P
Created by admin on Thu Jul 06 00:40:06 UTC 2023 , Edited by admin on Thu Jul 06 00:40:06 UTC 2023
PRIMARY
PUBCHEM
71587238
Created by admin on Thu Jul 06 00:40:06 UTC 2023 , Edited by admin on Thu Jul 06 00:40:06 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY